FDA Advisory Panel Day 2 Results: Semax and Epitalon Recommended, Emideltide Rejected — Full Two-Day Scorecard

The FDA Pharmacy Compounding Advisory Committee voted 8-5 to recommend Semax and 7-5 to recommend Epitalon for compounding access. Emideltide was the only compound rejected (6-7). Final two-day score: 6 out of 7 peptides recommended for the 503A Bulk Drug Substances List. Full vote breakdown and what it means for researchers.

Back to Blog